Curb complement to cure COVID-19

[1]  John D Lambris,et al.  Complement C3 vs C5 inhibition in severe COVID-19: Early clinical findings reveal differential biological efficacy , 2020, Clinical Immunology.

[2]  A. Perl,et al.  Therapeutic blockade of inflammation in severe COVID-19 infection with intravenous N-acetylcysteine , 2020, Clinical Immunology.

[3]  Alejandro Morales-Ortega,et al.  Imatinib for COVID-19: A case report , 2020, Clinical Immunology.

[4]  L. Dagna,et al.  Treating COVID-19 with colchicine in community healthcare setting , 2020, Clinical Immunology.

[5]  G. Keser,et al.  Cytokine storm in COVID-19: pathogenesis and overview of anti-inflammatory agents used in treatment , 2020, Clinical Rheumatology.

[6]  John D. Lambris,et al.  The first case of COVID-19 treated with the complement C3 inhibitor AMY-101 , 2020, Clinical Immunology.

[7]  C. Hedrich,et al.  COVID-19: Immunology and treatment options , 2020, Clinical Immunology.

[8]  John D Lambris,et al.  Complement as a target in COVID-19? , 2020, Nature Reviews Immunology.

[9]  David Berlin,et al.  Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: A report of five cases , 2020, Translational Research.

[10]  R. Kahwash,et al.  Will Complement Inhibition be the New Target in Treating COVID-19 Related Systemic Thrombosis? , 2020, Circulation.

[11]  P. Middleton,et al.  Ongoing Clinical Trials for the Management of the COVID-19 Pandemic , 2020, Trends in Pharmacological Sciences.

[12]  Geir Bjorklund,et al.  Individual risk management strategy and potential therapeutic options for the COVID-19 pandemic , 2020, Clinical Immunology.

[13]  P. Marchetti,et al.  Eculizumab treatment in patients with COVID-19: preliminary results from real life ASL Napoli 2 Nord experience. , 2020, European review for medical and pharmacological sciences.

[14]  Yan Zhao,et al.  The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China , 2020, Clinical Immunology.

[15]  J. Xiang,et al.  Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study , 2020, The Lancet.

[16]  D. Zeugolis,et al.  Cell‐Derived Extracellular Matrix‐Rich Biomimetic Substrate Supports Podocyte Proliferation, Differentiation, and Maintenance of Native Phenotype , 2020, Advanced functional materials.

[17]  G. Tsokos,et al.  Complement and coagulation cascades in trauma , 2019, Acute medicine & surgery.

[18]  S. Lorkowski,et al.  Kallikrein Cleaves C3 and Activates Complement , 2017, Journal of Innate Immunity.

[19]  G. Tsokos,et al.  C3a Enhances the Formation of Intestinal Organoids through C3aR1 , 2017, Front. Immunol..

[20]  G. Tsokos,et al.  Intracellular Activation of Complement 3 Is Responsible for Intestinal Tissue Damage during Mesenteric Ischemia , 2017, The Journal of Immunology.

[21]  Christian Drosten,et al.  Commentary: Middle East Respiratory Syndrome Coronavirus (MERS-CoV): Announcement of the Coronavirus Study Group , 2013, Journal of Virology.

[22]  E. Conway,et al.  Thrombin generates previously unidentified C5 products that support the terminal complement activation pathway. , 2012, Blood.

[23]  J. Thurman,et al.  Evidence for non-traditional activation of complement factor C3 during murine liver regeneration. , 2008, Molecular immunology.

[24]  S. Fleming,et al.  Complement, natural antibodies, autoantibodies and tissue injury. , 2006, Autoimmunity reviews.

[25]  J. Dunn,et al.  Mechanisms of activation of the classical pathway of complement by Hageman factor fragment. , 1983, The Journal of clinical investigation.

[26]  Henry P. Treffers,et al.  Complement , 1966, The Yale Journal of Biology and Medicine.

[27]  Roger B. Davis,et al.  Complement Deposition on the Surface of RBC After Trauma Serves A Biomarker of Moderate Trauma Severity: A Prospective Study. , 2019, Shock.